The group's principal activity is to develop proprietary drugs using pulmonary delivery technologies. The group is in development stage. The group develops nine respiratory and systemic (non-respiratory) therapies to be delivered through the group's metered solution inhaler and aerosol drug delivery system. The products of the group are respiratory drugs, which are used in the treatment of respiratory diseases such as asthma, chronic obstructive pulmonary diseases and cystic fibrosis. The group is developing a range of products to treat respiratory and systemic diseases in its proprietary pulmonary delivery systems, including the premaire(R) delivery system ('premaire') and tempo(tm) inhaler ('tempo'). The group acquires in-license portfolio of pulmonary delivery technologies to meet the market opportunity.
